Clinical trial
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in…
NCT00090051 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00090051 |
|---|---|
| Title | FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients |
| Official title | Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Biogen Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Rituximab, Fludarabine Phosphate, Cyclophosphamide |
| Enrollment | 552 |
| Start date | Jul 31, 2003 |
| Primary completion | Jul 23, 2008 |
| Completion | May 31, 2012 |
| First posted | Aug 25, 2004 |
| Last update posted | Aug 1, 2017 |
| Countries | Australia, Belgium, Canada, Denmark, France, Hungary, Italy, Netherlands, New Zealand, Norway, Poland, Romania and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: